PMC full text:Copyright/LicenseRequest permission to reuseOpen AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by-nc/4.0/.
Fig. 3
Treatments for Parkinson’s disease given in addition to DAT over time. CR controlled-release, CSAI continuous subcutaneous apomorphine infusion, DAT device-aided therapy, DBS deep brain stimulation, LCIG levodopa-carbidopa intestinal gel, PD Parkinson’s disease. aZero added PD medications represents monotherapy. bPatients with DAT monotherapy and only CR formulations of levodopa as additional oral co-medication. cNumber of added PD medications refers to those given in addition to DAT in the 6 months before baseline, 90 days before and 90 days after the 12-month timepoint, and 6 months before final DAT. Levodopa may be included in the number of added PD medications. p values were calculated using chi-square test
Images in this article
Click on the image to see a larger version.
